Chief Commercial Officer
Philina brings more than 15 years of biopharmaceutical industry leadership experience, with a strong track record in product commercialization, portfolio strategy, and successfully building high growth organizations while fostering a strong company culture. She currently serves as Chief Commercial Officer of Blueprint Medicines. Since joining the company in August 2014, she has been instrumental in building the company's portfolio from research-stage onwards, laying the groundwork for the commercial strategy that is driving the successful launches of AYVAKIT® (avapritinib) and GAVRETO® (pralsetinib). Philina also serves on the board of Fusion Pharmaceuticals. She earned a B.S. in Biochemistry from the University of Alberta, and a Ph.D. in Cell Biology from the Massachusetts Institute of Technology.
© 2024 NanoCanada. All rights reserved.